{"id":"W2566727384","doi":"","title":"進行・再発の薬物療法Pertuzumab（パージェタ(R)）を用いた進行乳癌症例１ Trastuzumab＋Pertuzumab＋DTX（1st line）（臨床報告）","year":2014,"lang":"ja","type":"article","venue":"Pharma Medica","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"","keywords":"Pertuzumab; Trastuzumab; Medicine; Internal medicine","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000909182,0.000260053,0.0003069648,0.0003685023,0.0005278853,0.0009922902,0.0002786854,0.0007106199,0.008292861],"category_scores_gemma":[0.00119189,0.0001419922,0.0003154925,0.0002280896,0.0006921063,0.0005992579,0.0002984993,0.0009470531,0.003337659],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008139535,"about_ca_system_score_gemma":0.0008126132,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001389648,"about_ca_topic_score_gemma":0.001237836,"domain_scores_codex":[0.9995938,0.00008218254,0.00002856957,0.00008562952,0.0001566437,0.00005314475],"domain_scores_gemma":[0.9996209,0.00009191048,0.00007130021,0.00003833829,0.0001135951,0.00006396346],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"case_report","study_design_scores_codex":[0.001647713,0.0007747263,0.009018139,0.0007605108,0.0002028827,0.002071799,0.00069676,0.0008091782,0.1619111,0.02788428,0.0289695,0.7652534],"study_design_scores_gemma":[0.000665121,0.004316345,0.0260445,0.0003140816,0.0005097054,0.01373187,0.0005435859,0.002192434,0.3159351,0.01833957,0.6172835,0.0001241311],"study_design_candidate":"case_report","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.4757352,0.08648252,0.03637886,0.02741287,0.003412091,0.0008066772,0.0008844096,0.001040039,0.3678473],"genre_scores_gemma":[0.817944,0.0208143,0.01978734,0.007990614,0.002080878,0.0002516198,0.0004298822,0.0001007364,0.1306007],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008292861,"threshold_uncertainty_score":0.02774239,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06880277521345375,"score_gpt":0.3906359419002953,"score_spread":0.3218331666868415,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}